While the usage of GLP-1 RAs and DPP-4 inhibitors was equivalent between the INS and non-INS groups in our cohort, suggesting the reliability of the comparison between these groups, the potential influence of incretin-related drugs on SWS in T2DM patients remains unclear. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.